Back to Report Store Home

Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D

  • Published: Nov-2011
  • Report Code: GBIHC150MR
  • Report Format: pdf

Description

GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017- Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

  • Country analysis of regulatory framework, investments, research clusters and overall support including the US, the UK, Germany, France, Japan, China, India, Singapore, Canada, and Australia

  • Investment Analysis in leading geographies

  • In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers

  • Market characterization data for stem cell research including population size, market potential, NIH funding, technology adoption framework and business models

  • Key drivers and restraints that have a significant impact on the market

  • Competitive landscape of global stem cell research including benchmarking of the leading companies. The key companies discussed in this report are Aastrom Biosciences, Athersys, Bioheart, Aldagen, Mesoblast, Geron Corporation, Advanced Cell Technology, Cytori Therapeutics, Pluristem Therapeutics, Medistem, NeoStem, Helix Therapeutics and StemCells Inc

  • Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2011 till date

Reasons To Buy

  • Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies

  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth

  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

  • Develop key strategic initiatives by studying the key strategies of top competitors

  • Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards